282 related articles for article (PubMed ID: 22089073)
21. Recommendations for the therapeutics of methotrexate in rheumatoid arthritis.
Murphy G; Coughlan R; Devlin J; FitzGerald O; McCarthy G
Ir Med J; 2009 Jun; 102(6):170-2. PubMed ID: 19722351
[No Abstract] [Full Text] [Related]
22. Corticosteroids as disease modifying drugs in rheumatoid arthritis treatment.
Yazici Y
Bull NYU Hosp Jt Dis; 2012; 70 Suppl 1():11-3. PubMed ID: 23259652
[TBL] [Abstract][Full Text] [Related]
23. [Methotrexate and non-steroidal anti-inflammatory agent combination in rheumatoid arthritis].
Bertin P; Carpentier N; Vergne P; Bonnet C; Bannwarth B; Dehais J; Treves R
Therapie; 1997; 52(2):133-7. PubMed ID: 9231508
[TBL] [Abstract][Full Text] [Related]
24. Rheumatoid arthritis: choice of antirheumatic treatment. Methotrexate first.
Prescrire Int; 2010 Feb; 19(105):30-4. PubMed ID: 20455343
[TBL] [Abstract][Full Text] [Related]
25. Methotrexate versus leflunomide in rheumatoid arthritis: what is new in 2011?
Singer O; Gibofsky A
Curr Opin Rheumatol; 2011 May; 23(3):288-92. PubMed ID: 21378570
[TBL] [Abstract][Full Text] [Related]
26. Limited end-user knowledge of methotrexate despite patient education: an assessment of rheumatologic preventive practice and effectiveness.
Sowden E; Hassan W; Gooden A; Jepson B; Kausor T; Shafait I; Haque S; Brockbank JE; Ley RW; Teh LS
J Clin Rheumatol; 2012 Apr; 18(3):130-3. PubMed ID: 22426579
[TBL] [Abstract][Full Text] [Related]
27. The pharmacogenetics of methotrexate.
Hider SL; Bruce IN; Thomson W
Rheumatology (Oxford); 2007 Oct; 46(10):1520-4. PubMed ID: 17586865
[TBL] [Abstract][Full Text] [Related]
28. Side effects and management of side effects of methotrexate in rheumatoid arthritis.
Albrecht K; Müller-Ladner U
Clin Exp Rheumatol; 2010; 28(5 Suppl 61):S95-101. PubMed ID: 21044440
[TBL] [Abstract][Full Text] [Related]
29. Longterm combination therapy of refractory and destructive rheumatoid arthritis with methotrexate (MTX) and intramuscular gold or other disease modifying antirheumatic drugs compared to MTX monotherapy.
Rau R; Schleusser B; Herborn G; Karger T
J Rheumatol; 1998 Aug; 25(8):1485-92. PubMed ID: 9712088
[TBL] [Abstract][Full Text] [Related]
30. [Use of NSAIDs in rheumatoid arthritis should be limited].
Lindberg M
Ugeskr Laeger; 2013 Apr; 175(15):1039-41. PubMed ID: 23582126
[TBL] [Abstract][Full Text] [Related]
31. Disappointing longterm results with disease modifying antirheumatic drugs. A practice based study.
Galindo-Rodriguez G; Aviña-Zubieta JA; Russell AS; Suarez-Almazor ME
J Rheumatol; 1999 Nov; 26(11):2337-43. PubMed ID: 10555887
[TBL] [Abstract][Full Text] [Related]
32. Risk factors associated with the cumulative survival of low-dose methotrexate in 273 Japanese patients with rheumatoid arthritis.
Ideguchi H; Ohno S; Ishigatsubo Y
J Clin Rheumatol; 2007 Apr; 13(2):73-8. PubMed ID: 17414533
[TBL] [Abstract][Full Text] [Related]
33. Effectiveness and retention rates of methotrexate in psoriatic arthritis in comparison with methotrexate-treated patients with rheumatoid arthritis.
Lie E; van der Heijde D; Uhlig T; Heiberg MS; Koldingsnes W; Rødevand E; Kaufmann C; Mikkelsen K; Kvien TK
Ann Rheum Dis; 2010 Apr; 69(4):671-6. PubMed ID: 19740904
[TBL] [Abstract][Full Text] [Related]
34. [Serious adverse effects of methotrexate therapy in patients with rheumatic arthritis].
Purokivi M; Myllykangas-Luosujärvi R; Jantunen E
Duodecim; 1998; 114(21):2187-90. PubMed ID: 11757107
[No Abstract] [Full Text] [Related]
35. Tumor necrosis factor therapy and the risk of serious infection and malignancy in patients with early rheumatoid arthritis: a meta-analysis of randomized controlled trials.
Thompson AE; Rieder SW; Pope JE
Arthritis Rheum; 2011 Jun; 63(6):1479-85. PubMed ID: 21360522
[TBL] [Abstract][Full Text] [Related]
36. Doxycycline in the treatment of rheumatoid arthritis--a pilot study.
Sreekanth VR; Handa R; Wali JP; Aggarwal P; Dwivedi SN
J Assoc Physicians India; 2000 Aug; 48(8):804-7. PubMed ID: 11273473
[TBL] [Abstract][Full Text] [Related]
37. The safety and efficacy of adding etanercept to methotrexate or methotrexate to etanercept in moderately active rheumatoid arthritis patients previously treated with monotherapy.
van der Heijde D; Burmester G; Melo-Gomes J; Codreanu C; Mola EM; Pedersen R; Freundlich B; Chang DJ;
Ann Rheum Dis; 2008 Feb; 67(2):182-8. PubMed ID: 17728331
[TBL] [Abstract][Full Text] [Related]
38. The facts about methotrexate in rheumatoid arthritis.
Bannwarth B; Vernhes JP; Schaeverbeke T; Dehais J
Rev Rhum Engl Ed; 1995; 62(7-8):471-3. PubMed ID: 8574608
[No Abstract] [Full Text] [Related]
39. Tumor necrosis factor alpha inhibitors and methotrexate: implications for deployed personnel.
Martin JJ
Aviat Space Environ Med; 2005 Dec; 76(12):1162-6. PubMed ID: 16370267
[TBL] [Abstract][Full Text] [Related]
40. Contemporary use of disease-modifying drugs in the management of patients with early rheumatoid arthritis in Norway.
Nikolaisen C; Kvien TK; Mikkelsen K; Kaufmann C; Rødevand E; Nossent JC
Scand J Rheumatol; 2009; 38(4):240-5. PubMed ID: 19229766
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
